HighGravityDataCurrent guidance
21 items
Biogen
Guidance from Biogen’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 29, 2026
Data checked
Jul 29, 2026
What changed in the Jul 29, 2026 release
Each item compared with the same item in the previous release (Apr 29, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Transaction to be accretive to Non-GAAP diluted EPS (Apellis) | for FY2027 | — | “accretive to Non-GAAP diluted EPS” | Filing ↗ |
| New | Transaction run rate synergies exiting 2027 | for FY2027 | — | “at least $250 million” | Filing ↗ |
| New | Total revenue growth | for FY2026 | — | “mid-single digit percentage” | Filing ↗ |
| New | Non-GAAP Diluted EPS - Approximate impact from acquired IPR&D and milestone charges | for FY2026 | — | “~($3.00)” | Filing ↗ |
| New | Non-GAAP Diluted EPS - Expected dilution from the Apellis acquisition | for FY2026 | — | “~($0.85)” | Filing ↗ |
| New | Non-GAAP Diluted EPS - Reported | for FY2026 | — | “$12.00 to $13.00” | Filing ↗ |
| New | Non-GAAP Diluted EPS - Underlying | for FY2026 | — | “$15.85 to $16.85” | Filing ↗ |
| New | Combined Non-GAAP R&D expense and Non-GAAP SG&A expense | for FY2026 | — | “between $2.65 billion and $2.70 billion” | Filing ↗ |
Show 6 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Apellis transaction | for FY2027 | “expected to be accretive” | — | Filing ↗ |
| Not restated | Total revenue | for FY2026 | “expected to decline by a mid-single digit percentage” | — | Filing ↗ |
| Not restated | Gross margin percentage | for FY2026 | “roughly consistent year-over-year” | — | Filing ↗ |
| Not restated | Gross margin percentage vs 2025 | for FY2026 | “roughly consistent year-over-year” | — | Filing ↗ |
| Not restated | Non-GAAP diluted EPS impact from TJ Biopharma felzartamab Greater China deal | for FY2026 | “approximately $0.55” | — | Filing ↗ |
| Not restated | Combined Non-GAAP R&D expense and Non-GAAP SG&A expense vs 2025 | for FY2026 | “roughly consistent year-over-year” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Total revenue | “decline by a mid-single digit percentage for 2026 as compared to 2025” | for FY2026 | GAAP-tied | Feb 6, 2026 | 2 | Filing ↗ |
| Total revenue | “expected to decline by a mid-single digit percentage” | for FY2026 | GAAP-tied | Apr 29, 2026 | 1 | Filing ↗ |
| Total revenue growth | “mid-single digit percentage” | for FY2026 | GAAP-tied | Jul 29, 2026 | 1 | Filing ↗ |
| Acquired IPR&D charges impact on Non-GAAP diluted EPS | “approximately $1.00” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Gross margin percentage | “roughly consistent year-over-year” | for FY2026 | GAAP-tied | Feb 6, 2026 | 1 | Filing ↗ |
| Gross margin percentage vs 2025 | “roughly consistent year-over-year” | for FY2026 | GAAP-tied | Apr 29, 2026 | 1 | Filing ↗ |
| Non-GAAP diluted EPS | “$15.25 to $16.25” | for FY2026 | Company-defined | Feb 6, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS - Approximate impact from acquired IPR&D and milestone charges | “~($3.00)” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS - Expected dilution from the Apellis acquisition | “~($0.85)” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS - Reported | “$12.00 to $13.00” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS - Underlying | “$15.85 to $16.85” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Non-GAAP diluted EPS impact from TJ Biopharma felzartamab Greater China deal | “approximately $0.55” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS Updated | “$14.25 to $15.25” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Combined Non-GAAP R&D expense and Non-GAAP SG&A expense | “between $2.65 billion and $2.70 billion” | for FY2026 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Combined Non-GAAP R&D expense and Non-GAAP SG&A expense vs 2025 | “roughly consistent year-over-year” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Non-GAAP effective tax rate | “between approximately 17% and 18%” | for FY2026 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Non-GAAP effective tax rate | “between approximately 17% and 18%” | for FY2026 | Company-defined | Feb 6, 2026 | 1 | Filing ↗ |
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Transaction to be accretive to Non-GAAP diluted EPS (Apellis) | “accretive to Non-GAAP diluted EPS” | for FY2027 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
| Apellis transaction | “expected to be accretive” | for FY2027 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Apellis transaction accretion | “expected to be accretive in 2027” | for FY2027 | Company-defined | Apr 29, 2026 | 1 | Filing ↗ |
| Transaction run rate synergies exiting 2027 | “at least $250 million” | for FY2027 | Company-defined | Jul 29, 2026 | 1 | Filing ↗ |
How one item moved
Total revenue, for FY2025 — every statement across the year, each linked to its filing.
How your Biopharma sector group guides
12 companies in Biopharma. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| BioMarin Pharmaceutical | Aug 6, 2026 | 19 changes |
| Halozyme Therapeutics | Aug 6, 2026 | 6 changes |
| Eli Lilly | Aug 5, 2026 | 5 changes |
| Amgen | Aug 4, 2026 | 5 changes |
| Gilead Sciences | Aug 4, 2026 | 15 changes |
| Moderna | Jul 31, 2026 | 8 changes |
| Neurocrine Biosciences | Jul 30, 2026 | 16 changes |
| Regeneron Pharmaceuticals | Jul 30, 2026 | 22 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2027 | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|---|
| Contract manufacturing revenue | — | — | 1 statement | — | — |
| Core pharmaceutical revenue | — | — | — | 1 statement | — |
| Cost of sales as a percentage of total revenue | — | — | — | 1 statement | — |
| Manufacturing revenue | — | — | 1 statement | — | — |
| Total revenue | — | 4 statements | 3 statements | 1 statement | — |
The full record for Biogen and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 29, 2026 | FY2026 Q2 | 0000875045-26-000073 | 8 | Open filing ↗ |
| Apr 29, 2026 | FY2026 Q1 | 0000875045-26-000042 | 12 | Open filing ↗ |
| Feb 6, 2026 | FY2025 Q4 | 0000875045-26-000011 | 4 | Open filing ↗ |
| Oct 30, 2025 | FY2025 Q3 | 0000875045-25-000047 | 11 | Open filing ↗ |
| Jul 31, 2025 | FY2025 Q2 | 0000875045-25-000035 | 7 | Open filing ↗ |
| May 1, 2025 | FY2025 Q1 | 0000875045-25-000014 | 5 | Open filing ↗ |
| Feb 12, 2025 | FY2024 Q4 | 0000875045-25-000004 | 7 | Open filing ↗ |
| Oct 30, 2024 | FY2024 Q3 | 0000875045-24-000030 | 6 | Open filing ↗ |
Not located in filing
2 values were detected in these releases but could not be matched to an exact sentence in the filing body, so they are not shown as guidance. We surface the count rather than drop it silently.
Show the 2 unmatched spans
| Span | Why | Filed |
|---|---|---|
| Apellis impact on Non-GAAP diluted EPS compounded annual growth rate = expected to materially increase Biogen's Non-GAAP diluted EPS compounded annual growth rate through the end of the decade | span gate: value not verbatim in filing | Apr 29, 2026 |
| operating margin = mid-single digit percentage point improvement | span gate: value not verbatim in filing | Oct 30, 2024 |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error